4 research outputs found
Anti-CD3 antibody treatment reduces scar formation in a rat model of myocardial infarction
Introduction: Antibody treatment with anti-thymocyte globulin (ATG) has been shown
to be cardioprotective. We aimed to evaluate which single anti-T-cell epitope antibody alters
chemokine expression at a level similar to ATG and identified CD3, which is a T-cell co-receptor
mediating T-cell activation. Based on these results, the effects of anti-CD3 antibody treatment on
angiogenesis and cardioprotection were tested in vitro and in vivo. Methods: Concentrations of
IL-8 and MCP-1 in supernatants of human peripheral blood mononuclear cell (PBMC) cultures
following distinct antibody treatments were evaluated by Enzyme-linked Immunosorbent Assay
(ELISA). In vivo, anti-CD3 antibodies or vehicle were injected intravenously in rats subjected to acute
myocardial infarction (AMI). Chemotaxis and angiogenesis were evaluated using tube and migration
assays. Intracellular pathways were assessed using Western blot. Extracellular vesicles (EVs) were
quantitatively evaluated using fluorescence-activated cell scanning, exoELISA, and nanoparticle
tracking analysis. Also, microRNA profiles were determined by next-generation sequencing. Results:
Only PBMC stimulation with anti-CD3 antibody led to IL-8 and MCP-1 changes in secretion, similar
to ATG. In a rat model of AMI, systemic treatment with an anti-CD3 antibody markedly reduced
infarct scar size (27.8% (Inter-quartile range; IQR 16.2–34.9) vs. 12.6% (IQR 8.3–27.2); p < 0.01). The
secretomes of anti-CD3 treated PBMC neither induced cardioprotective pathways in cardiomyocytes
nor pro-angiogenic mechanisms in human umbilical vein endothelial cell (HUVECs) in vitro. While
EVs quantities remained unchanged, PBMC incubation with an anti-CD3 antibody led to alterations
in EVs miRNA expression. Conclusion: Treatment with an anti-CD3 antibody led to decreased scar size in a rat model of AMI. Whereas cardioprotective and pro-angiogenetic pathways were unaltered
by anti-CD3 treatment, qualitative changes in the EVs miRNA expression could be observed, which
might be causal for the observed cardioprotective phenotype. We provide evidence that EVs are
a potential cardioprotective treatment target. Our findings will also provide the basis for a more
detailed analysis of putatively relevant miRNA candidates
A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas
Background
Cutaneous squamous cell carcinomas (cSCC) are the primary cause of premature deaths in patients suffering from the rare skin-fragility disorder recessive dystrophic epidermolysis bullosa (RDEB), which is in marked contrast to the rarely metastasizing nature of these carcinomas in the general population. This remarkable difference is attributed to the frequent development of chronic wounds caused by impaired skin integrity. However, the specific molecular and cellular changes to malignancy, and whether there are common players in different types of aggressive cSCCs, remain relatively undefined.
Methods
MiRNA expression profiling was performed across various cell types isolated from skin and cSCCs. Microarray results were confirmed by qPCR and by an optimized in situ hybridization protocol. Functional impact of overexpression or knock-out of a dysregulated miRNA was assessed in migration and 3D-spheroid assays. Sample-matched transcriptome data was generated to support the identification of disease relevant miRNA targets.
Results
Several miRNAs were identified as dysregulated in cSCCs compared to control skin. These included the metastasis-linked miR-10b, which was significantly upregulated in primary cell cultures and in archival biopsies. At the functional level, overexpression of miR-10b conferred the stem cell-characteristic of 3D-spheroid formation capacity to keratinocytes. Analysis of miR-10b downstream effects identified a novel putative target of miR-10b, the actin- and tubulin cytoskeleton-associated protein DIAPH2.
Conclusion
The discovery that miR-10b mediates an aspect of cancer stemness – that of enhanced tumor cell adhesion, known to facilitate metastatic colonization – provides an important avenue for future development of novel therapies targeting this metastasis-linked miRNA
p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa
Activation of apoptosis through transcriptional induction of Puma and Noxa has long been considered to constitute the critical (if not sole) process by which p53 suppresses tumor development, although G1/S boundary cell-cycle arrest via induction of the CDK inhibitor p21 has also been thought to contribute. Recent analyses of mice bearing mutations that impair p53-mediated induction of select target genes have indicated that activation of apoptosis and G1/S cell-cycle arrest may, in fact, be dispensable for p53-mediated tumor suppression. However, the expression of Puma, Noxa, and p21 was not abrogated in these mutants, only reduced; therefore, the possibility that the reduced levels of these critical effectors of p53-mediated apoptosis and G1/S-cell-cycle arrest sufficed to prevent tumorigenesis could not be excluded. To resolve this important issue, we have generated mice deficient for p21, Puma, and Noxa (p21−/−puma−/−noxa−/− mice). Cells from these mice were deficient in their ability to undergo p53-mediated apoptosis, G1/S cell-cycle arrest, and senescence. Nonetheless, these animals remained tumor free until at least 500 days, in contrast to p53-deficient mice, which had all succumbed to lymphoma or sarcoma by 250 days. Interestingly, DNA lesions induced by γ-irradiation persisted longer in p53-deficient cells compared to wild-type or p21−/−puma−/−noxa−/− cells, and the former failed to transcriptionally activate several p53 target genes implicated in DNA repair. These results demonstrate beyond a doubt that the induction of apoptosis, cell-cycle arrest, and possibly senescence is dispensable for p53-mediated suppression of spontaneous tumor development and indicate that coordination of genomic stability and possibly other processes, such as metabolic adaptation, may instead be critical
APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited skin and mucous membrane fragility disorder complicated by early-onset, highly malignant cutaneous squamous cell carcinomas (SCCs). The molecular etiology of RDEB SCC, which arises at sites of sustained tissue damage, is unknown. We performed detailed molecular analysis using whole-exome, whole-genome, and RNA sequencing of 27 RDEB SCC tumors, including multiple tumors from the same patient and multiple regions from five individual tumors. We report that driver mutations were shared with spontaneous, ultraviolet (UV) light-induced cutaneous SCC (UV SCC) and head and neck SCC (HNSCC) and did not explain the early presentation or aggressive nature of RDEB SCC. Instead, endogenousmutation processes associated with apolipoprotein B mRNA-editing enzymecatalytic polypeptide-like (APOBEC) deaminases dominated RDEB SCC. APOBEC mutation signatures were enhanced throughout RDEB SCC tumor evolution, relative to spontaneous UV SCC and HNSCCmutation profiles. Sixty-seven percent of RDEB SCC driver mutations was found to emerge as a result of APOBEC and other endogenous mutational processes previously associated with age, potentially explaining a > 1000-fold increased incidence and the early onset of these SCCs. Human papillomavirus-negative basal and mesenchymal subtypes of HNSCC harbored enhanced APOBEC mutational signatures and transcriptomes similar to those of RDEB SCC, suggesting thatAPOBECdeaminases drive other subtypes of SCC. Collectively, these data establish specific mutagenic mechanisms associated with chronic tissue damage. Our findings reveal a cause for cancers arising at sites of persistent inflammation and identify potential therapeutic avenues to treat RDEB SCC.</p